Recent News

• 09.08.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.05.2025 - Cantor Global Healthcare Conference 2025
• 08.27.2025 - Dyne Therapeutics to Present at Upcoming Investor Conferences
• 08.04.2025 - Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)
• 07.28.2025 - Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
• 07.02.2025 - Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
• 07.01.2025 - Catherine Novack
• 07.01.2025 - William Pickering, M.D.
• 07.01.2025 - Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock

Recent Filings

• 08.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 08.04.2025 - EX-99.1 EX-99.1
• 08.04.2025 - 8-K Current report
• 07.28.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.28.2025 - 8-K Current report
• 07.28.2025 - EX-99.1 EX-99.1
• 07.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 07.15.2025 - 4 Statement of changes in beneficial ownership of securities